Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the AD brain. Here the authors demonstrate that CSF p-tau217 shows better performance as an AD biomarker than p-tau181.
Bibliographic Details
| Main Authors: |
Shorena Janelidze,
Erik Stomrud,
Ruben Smith,
Sebastian Palmqvist,
Niklas Mattsson,
David C. Airey,
Nicholas K. Proctor,
Xiyun Chai,
Sergey Shcherbinin,
John R. Sims,
Gallen Triana-Baltzer,
Clara Theunis,
Randy Slemmon,
Marc Mercken,
Hartmuth Kolb,
Jeffrey L. Dage,
Oskar Hansson |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Publishing Group
2020-04-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-020-15436-0
|
|---|
